Global colorectal cancer research, 2007-2021: Outputs and funding

Mursheda Begum 1 | Grant Lewison 2 | Xiang Wang 3 | Philip D. Dunne 4 | Tim Maughan 5 | Richard Sullivan 2 | Mark Lawler 4

Abstract
The purpose of this study was to provide an evidence base for colorectal cancer research activity that might influence policy, mainly at the national level. Improvements in healthcare delivery have lengthened life expectancy, but within a situation of increased cancer incidence. The disease burden of CRC has risen significantly, particularly in Africa, Asia and Latin America. Research is key to its control and reduction, but few studies have delineated the volume and funding of global research on CRC. We identified research papers in the Web of Science (WoS) from 2007 to 2021, and determined the contributions of the leading countries, the research domains studied, and their sources of funding. We identified 62,716 papers, representing 5.7% of all cancer papers. This percentage was somewhat disproportionate to the disease burden (7.7% in 2015), especially in Eastern Europe. International collaboration increased over the time period in almost all countries except in China. Genetics, surgery and prognosis were the leading research domains. However, research on palliative care and quality-of-life in CRC was lacking. In Western Europe, the main funding source was the charity sector, particularly in the UK, but in most other countries government played the leading role, especially in China and the USA. There was little support from industry. Several Asian countries provided minimal contestable funding, which may have reduced the impact of their CRC research. Certain countries must perform more CRC research overall, especially in domains such as screening, palliative care and quality-of-life. The private-non-profit sector should be an alternative source of support.

Keywords
colorectal cancer, disease burden, funding, research domains, research outputs

What's new?
Active research is key to high-quality colorectal cancer (CRC) care. Here, the authors catalogued CRC research published between 2007 and 2021 with regard to study topics, funding, and the
The impact of CRC is measured in Disability Adjusted Life Years (DALYs), which take account both of early death and of time spent living with a disease. The increase in DALYs was 56% in Asia and in Latin America, and as much as 67% in Africa. CRC also increased its share of the overall cancer burden, with a rise of 9%, but with percentage increases of 27% in Latin America and 23% in Asia. Research is an essential aspect of high quality CRC care systems. Patients treated at research-active hospitals have better outcomes than those who are not. However, to date there has been little systematic consideration of the state of global CRC research. The only publication that focused on the disease by itself was a list of the 100 most influential papers. However, this did not address the geographical spread of the total output, or its variation with time. No previous study has determined if CRC research was performed in the research domains most important for the understanding, control and treatment of the disease.

Some bibliometric studies of overall cancer research in selected geographical areas have shown that CRC is neglected by researchers relative to its burden of disease. As a proportion of all cancer research, CRC research appeared to be only 50% of what would be expected, based on the percentage of deaths in India in 2004. CRC research was also only about half the percentage, relative to CRC DALYs in Europe, although the situation improved between 2002-2004 and 2011-2013. However, in China, CRC may have been somewhat over-researched in the period 2009 to 2018.

In this article, we have identified peer-reviewed published CRC research papers in the Web of Science (WoS, Clarivate Analytics) during the 12-year period 2007 to 2018, and examined their characteristics, including their sources of funding (this data source was used because we have developed specialized software over several decades that enables us to process and analyze the data rapidly. We recently added papers for the last 3 years, 2019 to 2021, to bring the results up to date). We also looked at CRC clinical trials, given their relevance to improved clinical care. Our aims were: (i) to determine which countries were performing well, and which countries needed to do more research; (ii) to delineate the research domains that were well studied and by whom and (iii) to analyze the main financial sponsors of the research.
Finally, we analyzed the funding sources for the papers published from 2009 to 2016. Since late 2008, the WoS has included explicit funding acknowledgement data as three searchable fields. However, it is also necessary to take account of implicit acknowledgements from paper addresses for government laboratories, those of commercial companies, and collecting charities (but not foundations). Because the names of financial sponsors are given in many different formats, we coded them with a three-part code that included an identifier, the sector and the country. We took account of the numerous false positive inclusions of commercial firms (mainly pharmaceutical companies) in the listings of funding sources where they had been included in the acknowledgement text in order to declare a possible conflict of interest. We then used two further macros to analyze funding contributions. The first macro added the codes from the two thesauruses (acknowledgements and addresses) to each of the papers, while the second macro calculated the contributions of each funder to each paper, based on a double fractionation, and hence to the support provided from each funding sub-sector to the CRC research of each country. The double fractionation took account of the proportion of addresses on each paper from each country, and of the numbers of funders from that country. For example, if France was one of three countries that had contributed to the paper, and there were two French national sources of funding (e.g., one public and one PNP), then each of these was deemed to have contributed one-sixth of the cost of the research.

### RESULTS

After the removal of 36 retracted papers, there were 62,716 papers in our database on CRC in the evaluable 12 year period, 2007 to 2018. The number doubled between 2007 and 2018, and the Annual Average Percentage Growth (AAPG) was 6.9%. The CRC papers represented 5.7% of the total publications for all cancers. This percentage rose slightly to 6.2% in 2014, but then dropped to 5.3% in 2016. However, it rose again to 6.3% in 2019 to 2021. CRC DALYs accounted for 7.7% of the cancer total in 2015, so research was less than proportionate by 31%. However, this shortfall varied greatly by geography, see Figure 1. Asia and Africa appear to be performing a proportionate amount of research, but the other geographical regions are publishing proportionally much less, particularly Eastern Europe (including Russia), where the relative disease burden is increasing. For this geographical region, there was virtually no correlation between the disease burdens from the different cancers and the amount of research performed on these cancers. Leukaemia was relatively over-researched, as was skin cancer, but lung cancer was under-researched by a factor of more than four, and CRC by a factor of more than two.

Figure 2 shows a plot for the leading individual countries in which their fractional paper counts in the last 5 years are compared with their wealth (GDP) in 2015. This plot shows a reasonable correlation, but does not take account of the relative disease burden from CRC in the different countries. Some of the high-performing countries had an increased CRC burden in 2015 compared with the world average
burden of 0.7%, such as Denmark (DK, 2.8%), the Netherlands (NL, 2.7%) and South Korea (KR, 2.1%), so their concomitant higher research outputs were appropriate. However, although India (IN, 0.34%) experienced less than half the world mean CRC disease burden, Brazil (BR, 0.9%) and especially, Switzerland (CH, 2.0%) experienced above the average value for CRC DALYs, and appear to be neglecting CRC in their research portfolios. The countries varied greatly in their AAPG values: the value for China was 24%, but for the USA it was 2.3% and for Germany it was only 0.6%. As a result, China accounted for 28% of the world total in 2018, and its output overtook that of the USA in 2014.

The leading individual institutions, with more than 900 addresses during the period 2007 to 2018, are listed in Table 2. There is a relative paucity of institutions from China, because for much of this period its output was quite low. The mean ratio of COLON to ONCOL is 10.3%, which is higher than the mean presence of CRC within cancer research (5.7%, v.s.) because many CRC papers have repeated addresses from different departments within the same institution. For example, the total for Harvard University also includes papers from the Massachusetts General Hospital and the Brigham & Women’s Hospital in Boston. This ratio is particularly high for Kaohsiung Medical University in Taiwan (24.6%) and the Leiden University Medical Centre in the Netherlands (23.5%), but low in the National Institutes of Health (5.0%) and the University of California system (6.3%) in the USA (overall, North America focuses relatively less on CRC than does Western Europe). However, the correlation between the two outputs is positive ($r^2 = 0.49$).

The partition of the papers by their research domain for the 12 year period shows that the three leading domains were genetics (21%), surgery and prognosis (both 18%). Within genetics, the two
largest areas were sporadic CRC (2598 papers, 19% of genetics) and inherited CRCs (2136 papers, 15%). Outputs of genomic signatures and of animal model papers were much smaller (437 and 388, respectively). Relative to the world, the USA over-performed in inherited genetics and models by 40%, while China under-performed in these two subfields by 71% and 38%, respectively. As a result, these subfields both decreased their shares of the world output in the genetics domain over the study period, especially in inherited genetics.

Although surgery accounted for 18% of all CRC research worldwide, it was only 10% in Europe, 8% in India, and 7% in China.\textsuperscript{6,13,14} This focus on surgical research reflects its primacy as the major treatment option for CRC. During the last 5 years, research on disease prognosis (PROG) overtook surgery, with 6623 papers (20% of the total in those years). There is an unusually small amount of research on palliative care (0.5%), which is almost universally neglected as a treatment modality, is researched preferentially in Japan (JP; ×2.1), South Korea (KR; ×1.5) and several European countries, but proportionately less in Iran (IR; ×0.2), India (IN; ×0.5) and China (CN; ×0.5). Radiotherapy is researched at an above-average level in South Korea (×2.0), the Netherlands (NL; ×1.7) and Belgium (BE; ×2.2). Chemotherapy (both conventional and targeted therapy) is researched relatively more highly in Japan (×1.8) and France (FR; ×1.6). Screening is actively researched only in the US (×2.5), the UK (×1.9), Canada (CA) and Spain (ES; ×1.8), and Australia (AU; ×1.7). It appears to be neglected in most other countries, particularly in Asia (all these ratios are statistically significant at \( P < 0.5\%), except for Belgium's commitment to radiotherapy research, for which \( P > 5\%\).

Those countries that are in relative terms neglecting certain research domains might benefit from additional international collaboration to balance their research portfolios. International collaboration varied greatly between countries, but has mostly been increasing with time. Although the percentage of foreign contributions to Chinese papers has declined between 2007-2010 and 2015-2018 (from 12% to 7%), the actual number of these contributions has risen from 32 per year to over 122 per year between the first and last quadrennia. The UK (×76%) and the USA (×64%) have increased their international collaboration the most over the study period. It is notable that the three most productive Asian countries (China, Japan and South Korea) collaborate much less than CRC researchers in Europe or North America, probably because of language and geography. This is also true for India (international papers = 27%), Iran (20%) and especially Turkey (10%).
TABLE 3  The relative concentration on 12 research domains within CRC research, 2014–18, for 26 leading countries

| Ratio | GENE | SURG | PROG | EPID | PATH | CHEM | RADI | SCRE | DIAG | TARG | QUAL | PALL |
|-------|------|------|------|------|------|------|------|------|------|------|------|------|
| CN    | 1.27 | 0.51 | 1.05 | 0.75 | 1.17 | 0.91 | 0.67 | 0.22 | 0.86 | 0.61 | 0.25 | 0.31 |
| US    | 0.91 | 0.91 | 0.86 | 1.56 | 0.80 | 0.70 | 0.84 | 2.47 | 1.07 | 0.77 | 1.24 | 1.45 |
| JP    | 0.73 | 2.05 | 1.10 | 0.65 | 1.01 | 1.65 | 1.14 | 0.23 | 0.86 | 2.03 | 0.54 | 1.00 |
| KR    | 0.91 | 1.49 | 1.14 | 1.16 | 1.00 | 0.87 | 1.95 | 0.60 | 0.65 | 0.55 | 0.50 | 1.03 |
| IT    | 0.89 | 1.19 | 0.89 | 0.70 | 0.85 | 1.25 | 1.28 | 0.68 | 1.07 | 2.21 | 0.80 | 0.43 |
| UK    | 0.60 | 1.32 | 1.26 | 1.19 | 1.03 | 0.86 | 1.19 | 1.87 | 1.77 | 0.77 | 2.07 | 1.31 |
| DE    | 1.02 | 1.13 | 1.18 | 0.86 | 1.24 | 0.89 | 1.06 | 1.15 | 0.98 | 1.13 | 0.84 | 0.42 |
| NL    | 0.75 | 1.49 | 1.11 | 1.27 | 0.70 | 1.21 | 1.73 | 1.37 | 1.13 | 0.85 | 4.64 | 2.91 |
| FR    | 0.75 | 1.33 | 0.92 | 0.83 | 0.83 | 1.53 | 1.12 | 1.14 | 1.11 | 2.05 | 1.41 | 1.16 |
| ES    | 0.95 | 0.96 | 1.04 | 0.93 | 0.68 | 1.00 | 0.93 | 1.77 | 1.46 | 1.46 | 0.79 | 0.62 |
| AU    | 1.01 | 0.89 | 1.08 | 1.23 | 0.98 | 1.03 | 1.31 | 1.69 | 0.86 | 1.43 | 2.10 | 2.55 |
| CA    | 0.80 | 1.08 | 0.97 | 1.42 | 0.71 | 1.62 | 1.26 | 1.84 | 1.11 | 0.90 | 2.01 | 1.98 |
| IN    | 0.84 | 0.53 | 0.40 | 0.34 | 0.79 | 1.18 | 1.01 | 0.18 | 0.86 | 0.41 | 0.17 | 0.04 |
| TR    | 0.89 | 1.15 | 1.12 | 0.88 | 1.35 | 0.83 | 0.92 | 0.53 | 0.79 | 1.89 | 0.85 | 1.22 |
| SE    | 0.97 | 1.42 | 1.11 | 1.65 | 0.95 | 0.80 | 0.83 | 0.64 | 0.83 | 0.49 | 3.05 | 3.09 |
| IR    | 1.46 | 0.20 | 0.66 | 0.91 | 0.88 | 1.15 | 0.72 | 0.66 | 1.27 | 0.51 | 1.22 | 1.89 |
| DK    | 0.98 | 1.24 | 1.10 | 1.75 | 1.12 | 0.99 | 0.91 | 1.29 | 1.50 | 0.99 | 1.72 | 1.17 |
| PL    | 1.28 | 0.86 | 0.69 | 0.76 | 1.38 | 0.79 | 0.81 | 0.36 | 1.15 | 0.52 | 1.10 | 1.37 |
| BR    | 1.32 | 0.83 | 0.85 | 0.57 | 1.15 | 1.15 | 1.49 | 0.34 | 0.81 | 0.62 | 2.30 | 3.01 |
| NO    | 0.97 | 1.18 | 1.64 | 1.40 | 0.78 | 0.98 | 1.52 | 1.31 | 0.45 | 0.35 | 0.82 | 1.47 |
| CH    | 0.97 | 1.10 | 1.33 | 0.68 | 1.50 | 0.95 | 1.19 | 0.77 | 2.05 | 1.17 | 0.44 | 0.85 |
| BE    | 0.70 | 1.28 | 1.22 | 0.46 | 0.64 | 1.26 | 2.20 | 0.53 | 0.68 | 2.62 | 0.41 | 0.09 |
| GR    | 1.29 | 0.95 | 1.17 | 0.56 | 1.16 | 1.06 | 0.06 | 0.67 | 1.22 | 1.52 | 0.50 | 1.02 |
| AT    | 1.17 | 1.05 | 1.41 | 0.66 | 1.73 | 1.93 | 0.91 | 0.61 | 0.64 | 1.81 | 0.69 | 0.10 |
| IL    | 0.92 | 1.08 | 0.52 | 1.17 | 0.69 | 0.77 | 0.97 | 1.35 | 1.48 | 1.01 | 0.00 | 1.07 |
| IE    | 0.64 | 1.20 | 1.10 | 0.91 | 1.17 | 0.88 | 1.29 | 1.75 | 2.81 | 0.43 | 4.32 | 2.30 |

Note: For ISO2 codes, see Table 1. For domain codes, see caption to Figure 3. Values that differ from unity with statistical significance P < 0.5% shown in bold type; values for P < 5% shown in roman type; values not statistically significant at P < 5% shown in italics.

Funding sources for the CRC research papers are shown in two charts, one for 13 European countries (Figure 3, top) and one for 10 non-European countries (Figure 3, bottom). For most European countries, the support from the private-non-profit (PNP) sector is greater than that from government, especially in the Scandinavian countries (DK, NO and SE), and in Belgium (BE), Switzerland (CH) and the UK. The second chart shows mainly the reverse, with government funding predominating, except for Iran (IR) and Turkey (TR). However, the composition of the PNP sector varies greatly, and the percentage shares are shown in Table 4. Collecting charities comprised just under one third of the total, but much more in the UK (67%) and the Netherlands (NL; 64%) reflecting the significant contribution to CRC research by Cancer Research UK and the Dutch Cancer Society. However, the funding contribution of cancer charities was marginal outside Europe, except in Australia (AU; 57%) and Canada (CA; 53%), and to a lesser extent in the USA (27%). In the other countries, the largest source of PNP support was the universities’ own funds, especially in Turkey (TR; 91%) and Iran (IR; 90%). This means that researchers received largely noncontestable research funding, with an inevitable lack of clarity in relation to peer review. Endowed foundations were notable in Denmark, where there are many small foundations, named for successful men and their wives (see Table 4),17 and a few large ones, such as Lundbeck and Novo Nordisk.

There was also a big variation in the governmental sector, between departments (under direct ministerial control) and agencies (intended to be independent). In some countries, notably Sweden (SE; 70%), Canada (CA; 61%), China (CN; 47%), Belgium (BE; 46%), Brazil (BR; 45%) and Norway (NO; 45%), local or regional authorities were substantial funders of this research (Table 4). The percentage contribution of government agencies, which usually have a contestable grant funding system with peer review, is particularly strong in France (FR; 90%), the USA (86%) and Switzerland (CH; 77%).

Industry funded only 4.9% of the research. This is much less than for lung cancer, which was reaching 8% in 2009 to 2013.18 Figure 3 shows that commercial funding is not a major contributor to CRC research, except in Belgium (BE; 13%) and Germany (DE; 10%). Overall, pharma companies contributed 46% of the total, and biotech companies, 15% (although the distinction between them is often not clear), and nonpharma
companies, 40%. The latter is an unusually high percentage, and may reflect the research emphasis on surgery, and its requirements for imaging and mechanical equipment, rather than chemotherapy. The leading pharma company was the Swiss company F Hoffman La Roche s.a., who provided support equivalent to that estimated for 181 papers. It was followed by Sanofi-Aventis (France, 82 papers), Pfizer (US, 65 papers), Merck KGaA (Germany, 64 papers), Bayer (Germany, 54 papers), Taiho Pharma (Japan, 51 papers) and AstraZeneca (UK) and Merck Inc. (US, both 38 papers). The leading nonpharma companies (Olympus in the USA, Covidien in Ireland and Philips nv in the Netherlands) provided much less support, equivalent to 21, 14 and 13 papers, respectively.

Finally, the international funding sector (primarily the European Union [EU] with its many research funding programs) funded the equivalent of 312 papers, 0.8% of the world total.

4 | DISCUSSION

Research is an important component of a country’s performance in the provision of evidence to underpin improvement of the care of its cancer patients. Because of the rising global burden of CRC, clinicians, scientists, government and state policy-makers have championed cancer research, from prevention, screening and diagnosis through to patient treatment and palliation. However, the amount of CRC research being performed is still low relative to the burden caused by the disease, especially in some world regions such as Eastern Europe. The quality of the research must also be considered.

The needs of CRC research in the individual countries will vary, because there are substantial differences in the impact of the disease. Our study reveals that certain countries, especially in Eastern Europe, are underperforming in CRC research relative to their GDP and need to do more to address the rising burden of this cancer. Countries such as Brazil and Switzerland may also need to change their research portfolios, to respond to the specific CRC-related challenges they face.

Recent technological advances in CRC diagnosis have underpinned enhanced clinical research activity. Because of improvements in genomic technologies, molecular profiling has become cheaper and more accessible for cancer researchers and clinical investigators. This has furthered our understanding of the molecular behavior of CRC. Moreover, knowledge of the associated clinical ramifications of molecular subtypes of CRC can help optimise treatment strategies and predict patient outcomes.

It is therefore not surprising that genetics/genomics is the most popular research domain, according to our study. But the research perhaps needs to be more proportionate to the needs of individual countries or regions, particularly in Central and Eastern Europe.

Broad technological advances have also been made in CRC therapy, including in surgery, radiotherapy and molecular-based treatment. These are therefore significant research domains. In particular, thanks to improvements in surgical techniques, increasing attention has been paid to this research domain, due to its primacy in the improvement of survival. However, there are significant regional variations, because of a lack of definitive research studies and this is very much reflected in our data.
Although CRC morbidity and mortality can be mitigated through appropriate screening and surveillance approaches, these research areas appear to be neglected in many countries, especially in Asia. This may be due to a shortage of human and financial resources, but also a lack of awareness of the need for these types of research. Tumor heterogeneity in CRC has been identified, and many approaches have been developed to determine patient prognosis based on the biology of individual tumors and personal characteristics. Thus, research on the prognosis of CRC has attracted more and more attention, and its output recently overtook that in genetics.

Palliative care research has been severely neglected, perhaps because it requires more collaboration from workers from several different disciplines who provide support to patients. However, recently it has received more attention, although it still represents barely 1% of the total research output.

Alternative sources of funding are evidently needed and should be actively sought by governments and societies. This will involve fiscal encouragement to the charitable sector, and the formation and support of medical research charities in geographical areas where they do not currently exist. However, this is particularly difficult in LMICs, where medical research and science are usually low on the list of national priorities. In this context, international collaboration can be an important source of additional funding, and can also provide a level of peer review for national funding bodies. For example, in the Czech Republic international collaborative proposals that are deemed fundable by say an EU funding scheme, but fall just below the overall budget threshold, may be funded at national level following the positive peer review.

The study has some limitations. We used a single database of research outputs (the WoS). This has some language biases, omitting a proportion of clinical papers in national languages, especially from East Asia. For example, the papers from China are in much more basic/discovery research on average than those from the rest of the world, so it is likely that a number of clinical papers will have been omitted from the WoS. A few funding sources could not be coded, as no information about them was available on the Web, or they were given in the acknowledgements only as initials. There were also some funding references where their name was not given, only the grant number, and not all of these sources could be identified. Nonetheless, the data accumulated and evaluated in this study provide crucial

### Table 4
The funding sub-sectors contributing to the total government and private-non-profit sectoral contributions to CRC research in 23 leading countries, 2007 to 2016

| ISO2 | Government | Private-non-profit |
|------|------------|--------------------|
|      | DEPT | AGENCY | LA | CHAR | FDN | HOSP | UNIV | OTH |
| AU   | 8.1  | 56     | 36 | 57   | 2.9 | 9.7  | 21   | 9.4 |
| BE   | 48   | 6.4    | 45 | 51   | 0.8 | 23   | 23   | 1.6 |
| BR   | 4.9  | 50     | 45 | 14   | 0   | 22   | 58   | 5.6 |
| CA   | 3.0  | 36     | 61 | 53   | 2.1 | 9.5  | 26   | 10  |
| CH   | 17   | 77     | 5.9| 53   | 23  | 8.5  | 8.4  | 7.0 |
| CN   | 23   | 31     | 47 | 1.1  | 4.5 | 1.5  | 87   | 5.5 |
| DE   | 27   | 61     | 12 | 30   | 24  | 4.1  | 26   | 15  |
| DK   | 58   | 19     | 22 | 30   | 45  | 14   | 7.6  | 3.5 |
| ES   | 17   | 48     | 35 | 27   | 22  | 8.7  | 13   | 29  |
| FR   | 4.7  | 90     | 5.4| 60   | 0.8 | 9.1  | 7.5  | 23  |
| GR   | 72   | 28     | 0  | 2.5  | 14  | 4.6  | 52   | 26  |
| IN   | 41   | 54     | 4.8| 4.5  | 12  | 9.3  | 72   | 2.6 |
| IR   | 98   | 0      | 2.0| 0    | 3.7 | 90   | 6.5  |     |
| IT   | 29   | 58     | 13 | 52   | 16  | 3.5  | 24   | 4.5 |
| JP   | 76   | 23     | 0.6| 17   | 27  | 7.1  | 25   | 24  |
| KR   | 93   | 5.9    | 0.8| 0.1  | 9.8 | 22   | 65   | 2.6 |
| NL   | 27   | 72     | 0  | 64   | 8.5 | 10   | 7.5  | 9.5 |
| NO   | 4    | 51     | 45 | 45   | 7.9 | 28   | 12   | 7.7 |
| PL   | 67   | 31     | 2.5| 1.7  | 0   | 86   | 12   |     |
| SE   | 0.1  | 30     | 70 | 38   | 23  | 9.3  | 19   | 10  |
| TR   | 100  | 0      | 0  | 0    | 1.0 | 91   | 7.8  |     |
| UK   | 67   | 33     | 0.2| 67   | 7.0 | 7.1  | 11   | 7.7 |
| US   | 10   | 86     | 3.3| 27   | 15  | 9.5  | 33   | 15  |
| Mean | 29   | 36     | 27 | 33   | 13  | 11   | 32   | 11  |

Note: Figures are percentages of total government and PNP support. ISO2 codes for countries in Table 1.
Abbreviations: AGENCY, government agency; CHAR = collecting charities; DEPT, government department; FDN, endowed foundations; HOSP, hospital own funds; LA, local or regional government; OTH, other nonprofit (eg, professional associations); UNIV, university own funds.
intelligence to help guide our collective research efforts to understand CRC and deliver research-informed insights that will help reduce its global burden.

AUTHOR CONTRIBUTIONS
Conceptualization: Richard Sullivan, Mark Lawler. Data curation: Mursheda Begum. Formal Analysis: Mursheda Begum, Grant Lewison. Funding acquisition: Tim Maughan, Mark Lawler. Investigation: Mursheda Begum, Grant Lewison. Methodology: Grant Lewison. Project administration: Grant Lewison. Resources: Richard Sullivan. Software: Philip Roe, Evaluametrics Ltd. Supervision: Grant Lewison. Validation: Xiang Wang, Philip D. Dunne, Tim Maughan, Richard Sullivan, Mark Lawler. Visualization: Grant Lewison. Writing—original draft: Grant Lewison, Mark Lawler, Richard Sullivan. Writing—review & editing: All authors. The work reported in the paper has been performed by the authors, unless clearly specified in the text.

ACKNOWLEDGEMENT
We are grateful to Philip Roe of Evaluametrics Ltd for the provision of the macros (computer programs) used for the analysis.

FUNDING INFORMATION
This study was supported by a Medical Research Council—Cancer Research UK (MRC—CRUK) Stratified Medicine in Colorectal Cancer (S:CORT) Program Grant and a grant from Health Data Research UK.

CONFLICT OF INTEREST
Mark Lawler and Richard Sullivan are in receipt of an unrestricted educational grant from Pfizer for research unrelated to this work. Mark Lawler has received honoraria for speaking engagements from Pfizer, EMF Serono, Novartis, Bayer and Roche for research unrelated to this work. Tim Maughan has received consultancy fees from AstraZeneca and Pierre-Fabre unrelated to this work. The other authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Grant Lewison https://orcid.org/0000-0002-4493-1216

REFERENCES
1. Oeppen J, Vaupel JW. Broken limits to life expectancy. Science. 2002; 296(5570):1029-1031.
2. Rousson V, Paccaud F. A set of indicators for decomposing the secular increase of life expectancy. Popul Health Metr. 2010;8:18. doi:10.1186/1478-7954-8-18
3. Boudoulas KD, Triposkaidis F, Stefanadis C, Boudoulas H. The endlessness of medicine, continuous increase in life expectancy and constant role of the physician. Hellenic J Cardiol. 2017;58(5):322-330.
4. Bor J, Herbst AJ, Newell M, Barnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013;34(6122):961-965.
5. Solis P, Garcia-Guerrero VM. Divergent paths to low mortality? The increase in life expectancy and the inequality in the number of lived years in Latin America and Europe. Estud Demogr Urbanos. 2019;34(2):365-393.
6. Li A, Lewison G. Chinese cancer research in 2009–18 and the disease burden. Cancer Manag Res. 2020;12:5031-5040. doi:10.2147/CMAR.5253276
7. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683-691.
8. Siegel RL, Miller KD, Sauer AG, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145-164.
9. World Health Organization Global Health Estimates 2015: DALYs by cause, age, sex, by country and by region, 2000-2015. Geneva, World Health Organization, 2016. http://www.who.int/healthinfo/global_burden_disease/en/
10. Lawler M, Alsina D, Adams RA, et al. Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut. 2018;67(1):179-193.
11. Selby P, Liu L, Downing A, et al. How can clinical research improve European health outcomes in cancer? J Cancer Policy. 2019;20:100182. doi:10.1016/j.jcpc.2019.100182
12. Wrafter PF, Connelly TM, Khan J, et al. The 100 most influential manuscripts in colorectal cancer: a bibliometric analysis. Surgeon. 2016;14(6):327-336.
13. Sullivan R, Badwe RA, Rath GK, et al. Cancer research in India: national priorities, global results. Lancet Oncol. 2014;15(6):e213-e222. doi:10.1016/S1470-2045(14)70109-3
14. Begum M, Lewison G, Lawler M, Sullivan R. Mapping the European cancer research landscape: an evidence base for national and pan-European research and funding. Eur J Cancer. 2018;100:75-84.
15. Lewison G. The definition of biomedical research subfields with title keywords and application to the analysis of research outputs. Res Eval. 1996;6(1):25-36.
16. World Bank. 2017. GDP (current US$): World Bank national accounts data, and OECD National Accounts data files. http://data.worldbank.org/indicator/NY.GDP.MKTP.CD
17. Begum M, Lewison G. Web of science research funding information: methodology for its use in analysis and evaluation. J Sci Res. 2017;6(2):65-72. doi:10.5530/jscires.6.2.12
18. Begum M, Urquhart I, Lewison G, et al. Research on lung cancer and its funding. 2004-2018. eCancerMedicalScience. 2020;14:1132. doi:10.3332/ecancer.2020.1132
19. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009;18:1688-1694.
20. Markovic S, Dimitrijevic I, Zogovic B, et al. Current trends in clinical genetics of colorectal cancer. J BUON. 2016;21(5):1042-1049.
21. Palma S, Zwenger AO, Croce MV, et al. From molecular biology to clinical trials: toward personalized colorectal cancer therapy. Clin Colorectal Cancer. 2016;15:104-115.
22. Moris D, Pawlik TM. Personalized treatment in patients with colorectal liver metastases. J Surg Res. 2017;216:26-29.
23. Dunne PD, Alderdice M, O’Reilly PG, et al. Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification. Nat Commun. 2017;8:15657. doi:10.1038/s41567-018-0032-2
24. Morris EJA, Finan PJ, Spencer K, et al. Wide variation in the use of radiotherapy in the management of surgically treated rectal cancer across the English National Health Service. Clin Oncol. 2016;28:522-531.
25. Albert MR, Atallah SB, DeBeche-Adams TC, et al. Transanal minimally invasive surgery (TAMIS) for local excision of benign neoplasms and early-stage rectal cancer: efficacy and outcomes in the first 50 patients. Dis Colon Rectum. 2013;56:301-307.
26. Andratschke NH, Nieder C, Heppt F, et al. Stereotactic radiation therapy for liver metastases: factors affecting local control and survival. Radiat Oncol. 2015;10:69.

27. MacFarlane JK, Ryall RDH, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341(8843):457-460.

28. Carlsen E, Schlichting E, Guldrog I, et al. Effect of the introduction of total mesorectal excision for the treatment of rectal cancer. Brit J Surg. 1998;85(4):526-529.

29. Mahar AL, Compton C, Halabi S, et al. Personalizing prognosis in colorectal cancer: a systematic review of the quality and nature of clinical prognostic tools for survival outcomes. J Surg Oncol. 2017;116(8):969-982.

How to cite this article: Begum M, Lewison G, Wang X, et al. Global colorectal cancer research, 2007-2021: Outputs and funding. Int J Cancer. 2023;152(3):470-479. doi:10.1002/ijc.34279